Ensign Peak Advisors Inc Sells 35,172 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Ensign Peak Advisors Inc trimmed its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 1.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,244,828 shares of the company’s stock after selling 35,172 shares during the period. Ensign Peak Advisors Inc owned approximately 3.84% of Phathom Pharmaceuticals worth $23,122,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Inspirion Wealth Advisors LLC lifted its stake in Phathom Pharmaceuticals by 4.3% in the 2nd quarter. Inspirion Wealth Advisors LLC now owns 36,634 shares of the company’s stock valued at $377,000 after acquiring an additional 1,500 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Phathom Pharmaceuticals by 12.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,573 shares of the company’s stock worth $208,000 after buying an additional 2,172 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Phathom Pharmaceuticals by 42.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,071 shares of the company’s stock valued at $104,000 after acquiring an additional 2,987 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Phathom Pharmaceuticals by 65.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 10,989 shares of the company’s stock valued at $117,000 after acquiring an additional 4,363 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in Phathom Pharmaceuticals by 17.1% during the second quarter. Rhumbline Advisers now owns 55,178 shares of the company’s stock worth $568,000 after acquiring an additional 8,075 shares in the last quarter. 99.01% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PHAT has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Monday, August 12th. Needham & Company LLC restated a “buy” rating and set a $26.00 price objective on shares of Phathom Pharmaceuticals in a research report on Friday, September 13th. Finally, The Goldman Sachs Group upped their price target on shares of Phathom Pharmaceuticals from $10.00 to $12.00 and gave the company a “neutral” rating in a research note on Friday, August 9th.

Phathom Pharmaceuticals Stock Down 1.5 %

Shares of PHAT stock opened at $18.43 on Monday. The business has a fifty day simple moving average of $14.18 and a 200 day simple moving average of $11.58. The company has a market cap of $1.10 billion, a P/E ratio of -4.18 and a beta of 0.71. Phathom Pharmaceuticals, Inc. has a twelve month low of $6.07 and a twelve month high of $19.71.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($1.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.39) by $0.04. The company had revenue of $7.32 million for the quarter, compared to analyst estimates of $5.65 million. As a group, equities research analysts anticipate that Phathom Pharmaceuticals, Inc. will post -6.03 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Terrie Curran sold 33,848 shares of Phathom Pharmaceuticals stock in a transaction on Monday, July 15th. The shares were sold at an average price of $11.72, for a total transaction of $396,698.56. Following the transaction, the insider now owns 377,734 shares in the company, valued at $4,427,042.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, COO Azmi Nabulsi sold 10,901 shares of the stock in a transaction on Monday, July 15th. The shares were sold at an average price of $11.72, for a total transaction of $127,759.72. Following the transaction, the chief operating officer now directly owns 240,421 shares of the company’s stock, valued at $2,817,734.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Terrie Curran sold 33,848 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $11.72, for a total value of $396,698.56. Following the completion of the sale, the insider now owns 377,734 shares of the company’s stock, valued at $4,427,042.48. The disclosure for this sale can be found here. Insiders sold 49,074 shares of company stock valued at $575,147 over the last quarter. 24.10% of the stock is owned by company insiders.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.